Tag
This study reveals that elevated 12,13-diHOME levels, reflecting brown adipose tissue activation during targeted temperature management after cardiac arrest, correlate with improved survival and distinct immunometabolic profiles.
Baseline lung allograft dysfunction (BLAD) affects over 60% of bilateral lung transplant recipients, associates with increased mortality, and influences long-term lung function trajectories. Risk factors include higher BMI, prolonged ICU st
Systemic relapse after stage I melanoma, though rare, portends higher tumor burden and poorer survival compared with relapse after stage II/III disease, as evidenced by data from 365 metastatic melanoma patients in the Spanish Melanoma Regi
Emerging evidence reveals gut microbiota profiles correlate with disease severity and survival in idiopathic pulmonary fibrosis, highlighting potential microbial biomarkers and treatment modifiers.
This review synthesizes recent evidence demonstrating persistent racial and ethnic disparities in treatment initiation and survival among patients with advanced endometrial cancer, highlighting the critical influence of socioeconomic status
This study reveals mycophenolate and azathioprine do not improve 3-year transplant-free survival or lung function in fibrotic ILD, with potential harm in select subtypes. Robust randomized trials remain essential for guiding immunosuppressi
Medicaid expansion under the Affordable Care Act is associated with reduced mortality in patients under 65 diagnosed with colorectal cancer and synchronous liver metastasis, notably improving outcomes for those receiving surgical and system
Centralized multidisciplinary retinoblastoma care incorporating telemedicine and international partnership at KHCC improved survival and globe salvage rates to levels comparable with high-income countries, demonstrating a scalable model for
This phase 2 trial compares CPX-351 with CLAG-M chemotherapy in medically unfit adults with AML, finding CLAG-M achieves better 3-month survival and response rates, especially in patients with proliferative disease, suggesting intensive the
Analysis of SEER data from 2000-2021 reveals incidence, survival trends, and demographic disparities in US patients with myeloproliferative neoplasms, highlighting improved outcomes particularly in primary myelofibrosis and areas for furthe
Vulvar cancer exhibits significant recurrence rates, predominantly local, with survival declining sharply after recurrence. Awareness of recurrence-associated symptoms enhances early detection. Surgery remains pivotal in management, with fr
Charcot neuro-osteoarthropathy (CNO) in people with diabetes is linked to frequent emergency hospitalizations, substantial risk of limb amputation, and reduced survival, highlighting urgent need for intensified multidisciplinary care.
The ANDROMEDA phase 3 trial demonstrates that adding subcutaneous daratumumab to VCd therapy markedly improves hematologic and organ responses, leading to better progression-free and overall survival in newly diagnosed AL amyloidosis patien
This article analyzes 40-year trends in incidence, mortality, and survival of endometrial, ovarian, and cervical cancers among Nordic women aged 0-49, highlighting evolving epidemiology and implications for age-specific prevention.
Enfortumab vedotin (EV) therapy in advanced urothelial carcinoma is frequently associated with cutaneous adverse events (cAEs). These EV-induced skin toxicities correlate independently with improved progression-free and overall survival, ev
A large Texas registry study found that treatment delays beyond 6 weeks were independently associated with worse survival in early-onset colorectal cancer, with language barriers identified as a potentially modifiable contributor.
This study found that advanced high-grade serous ovarian cancers from short-term survivors had more fibroblasts and stromal invasion signals, while tumors from long-term survivors showed stronger immune pathways, suggesting the tumor microe
A nationwide French cohort study reveals that advanced NSCLC patients completing 2 years of pembrolizumab maintain excellent survival outcomes, with most remaining treatment-free and immunotherapy rechallenge being uncommon.
In 2026, approximately 2.1 million new cancer cases and 626,140 deaths are projected in the U.S. Advances in prevention, early detection, and treatment have increased survival rates and averted millions of deaths, yet disparities and rising
Randomised trials show breast surgery improves local disease control but not overall survival in de novo metastatic breast cancer.
